Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02712723 · ClinicalTrials.gov registry record · Phase 2

Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by Qamar Khan.

Active
Registry status
Phase 2
Development phase
121
Enrollment target
13
Study locations

NCT02712723: Active Phase 2 study of Breast Cancer, sponsored by Qamar Khan.

NCT02712723 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by Qamar Khan. The registered enrollment target is 121 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 13 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02712723, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by Qamar Khan.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
121 participants
Enrollment target
13
Study locations

Study Summary

The purpose of this study is to determine if ribociclib in combination with letrozole for 24 weeks as neoadjuvant endocrine therapy increases the proportion of women with Pre-operative Endocrine Prognostic Index (PEPI) score of 0 at surgery compared to patients treated with letrozole alone therefore allowing more patients excellent outcomes without chemotherapy.

Conditions Studied

Breast Cancer

Interventions

  • DRUG Placebo
  • DRUG Letrozole
  • DRUG Ribociclib

Study Locations (13)

Kansas

  • University of Kansas Cancer Center - West - Kansas City
  • University of Kansas Cancer Center - Overland Park - Overland Park
  • University of Kansas Cancer Center - Westwood - Westwood

Missouri

  • University of Kansas Cancer Center - South - Kansas City
  • University of Kansas Cancer Center - North - Kansas City
  • University of Kansas Cancer Center - Lee's Summit - Lee's Summit

California

  • City of Hope National Medical Center - Duarte
  • Cancer Research Collaboration - Santa Ana

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

Florida

  • University of Miami Sylvester Comprehensive Cancer Center - Deerfield Beach

Massachusetts

  • Massachusetts General Hospital - Boston

New York

  • Columbia University Medical Center - New York

Wisconsin

  • University of Wisconsin Carbone Cancer Center - Madison

Trial Details

FieldValue
Enrollment Target 121 participants
Start Date 2016-02
Est. Completion 2026-12
Phase Phase 2

Sponsor

Qamar Khan

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02712723

The ClinicalTrials.gov registry entry for NCT02712723 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Qamar Khan, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02712723 reports 13 study locations spanning 8 distinct geographic areas - top geographies include Kansas, Missouri, California.

Frequently Asked Questions

What is clinical trial NCT02712723 about?

NCT02712723 is a clinical study titled "Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer". The purpose of this study is to determine if ribociclib in combination with letrozole for 24 weeks as neoadjuvant endocrine therapy increases the proportion of women with Pre-operative Endocrine Prognostic Index (PEPI) score of 0 at surgery compared to patients treated with letrozole alone therefore...

What is the current status of trial NCT02712723?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2016-02. Estimated completion is 2026-12.

What conditions does trial NCT02712723 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT02712723?

The interventions under investigation include: Placebo (DRUG), Letrozole (DRUG), Ribociclib (DRUG).

Who is sponsoring clinical trial NCT02712723?

This trial is sponsored by Qamar Khan, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02712723 being conducted?

This trial has 13 study locations across Arkansas, California, Florida, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.